There is a moment buried in the April 24 court transcript that deserves much more attention.
At the heart of the lawsuit over compounded tirzepatide lies a simple but explosive discrepancy. The FDA removed tirzepatide from the drug shortage list based on a supply figure provided by Eli Lilly. That figure was used to justify cutting off access to compounded versions of the drug, effectively handing full market control back to Lilly.
But here is the problem…
Keep reading with a 7-day free trial
Subscribe to On The Pen to keep reading this post and get 7 days of free access to the full post archives.